Richard joined Omega Funds in 2008. His career spans 25 years in private equity investing and strategic consulting, all within life science and healthcare. At Omega, he is a member of the firm’s investment committee and acts as President of Omega Fund Management LLC; his primary investment focus is in drug discovery and development companies, and is actively involved in the firm’s secondary buyout practice and investments in academic spinouts.
Previously, Richard was a General Partner at MVM Life Science Partners, a life science-focused venture capital firm, where he founded the firm’s US investment operations. He was previously a Vice President at Saunders, Karp & Megrue (SKM), where he specialized in healthcare growth capital and leveraged buyout transactions. Prior to SKM, now known as Apax Partners Inc., Richard was a Manager at LEK Consulting, providing strategic advice to life science companies; he consulted for more than three dozen small and large biotechnology firms. He was also an Associate with the M&A investment bank BT Wolfensohn. He has served on a number of boards of biotechnology, specialty pharmaceutical, and medical device companies. He serves on the advisory boards of the Deshpande Center at the Massachusetts Institute of Technology. Richard earned his AB and MBA degrees from Harvard University.